A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse.

Trial Profile

A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Temsirolimus (Primary) ; Bendamustine; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BERT
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Results (n=34) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top